Case Study: Biopharmaceutical Company achieves phishing CTR below the 3.8% industry benchmark with Proofpoint

Helping a Biopharmaceutical Company Reduce CTR on Phishing Emails Below the Industry Benchmark

A publicly traded biopharmaceutical company based in San Diego with 1,500+ employees and nearly $350M in revenue faced persistent email risk: Mimecast’s Secure Email Gateway blocked many threats but spear phishing, BEC and ATO attacks still reached inboxes, CTR on phishing simulations stayed above the industry benchmark (3.8%), and rule‑based SEGs created heavy admin overhead despite regular training.

The company deployed Tessian Defender, a low‑maintenance inbound email security solution that provides automated detection, customized in‑the‑moment warnings, and one‑click remediation. Deployment took under an hour, is managed by a single administrator, and within six months CTR fell well below the 3.8% benchmark; Tessian also detected and prevented 6,836 inbound threats in a three‑month period and substantially reduced investigation and remediation time.